The impact of the 21-gene recurrence score assay in decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy | אונקוטסט
מאמרים בשיתוף אונקוטסט
מאמרים בשיתוף אונקוטסט
אונקוטסט > מאמרים בשיתוף אונקוטסט > The impact of the 21-gene recurrence score assay in decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy

עדכונים > מאמרים בשיתוף אונקוטסט

The impact of the 21-gene recurrence score assay in decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy

The impact of the 21-gene recurrence score assay in decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy

Geffen et al, 2011 Annals of Oncology (Oxford University Press)

http://www.medscape.com/viewarticle/752325

Authors:

Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, Delgado B, Bayme M, Koretz M

צור קשר